These discoveries were consistent to some extent with the finding that inhibition of CXCL9 expression or protein activity will weaken the therapeutic effect of anti-PD-1/PD-L1 therapy and lead to a dismal prognosis of melanoma patients (19). This evidence concerns the gene CD274 and melanoma.